Connection

THOMAS WHEELER to Immunohistochemistry

This is a "connection" page, showing publications THOMAS WHEELER has written about Immunohistochemistry.
Connection Strength

0.686
  1. Application of immunohistochemistry to the genitourinary system (prostate, urinary bladder, testis, and kidney). Arch Pathol Lab Med. 2008 Mar; 132(3):432-40.
    View in: PubMed
    Score: 0.217
  2. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol. 1999 Aug; 12(8):751-5.
    View in: PubMed
    Score: 0.030
  3. Immunohistochemical and ultrastructural study of rhabdosphincter component of the prostatic capsule. J Urol. 1997 Nov; 158(5):1819-28.
    View in: PubMed
    Score: 0.027
  4. Verumontanum mucosal gland hyperplasia. Am J Surg Pathol. 1995 Jan; 19(1):30-6.
    View in: PubMed
    Score: 0.022
  5. Tamm-Horsfall protein in bladder tissue. Morphologic spectrum and clinical significance. Am J Surg Pathol. 1994 Jun; 18(6):615-22.
    View in: PubMed
    Score: 0.021
  6. Paraganglia of the prostate. Location, frequency, and differentiation from prostatic adenocarcinoma. Am J Surg Pathol. 1994 Apr; 18(4):412-20.
    View in: PubMed
    Score: 0.021
  7. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun; 189(6):2039-46.
    View in: PubMed
    Score: 0.019
  8. Thymic carcinoma. A clinicopathologic study of 13 cases. Am J Surg Pathol. 1990 Feb; 14(2):151-66.
    View in: PubMed
    Score: 0.015
  9. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.014
  10. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol. 2007 Oct; 38(10):1501-7.
    View in: PubMed
    Score: 0.013
  11. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131(1):18-43.
    View in: PubMed
    Score: 0.013
  12. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 01; 25(1):118-45.
    View in: PubMed
    Score: 0.012
  13. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol. 2007 Feb; 38(2):299-307.
    View in: PubMed
    Score: 0.012
  14. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.012
  15. Neuroanatomy of the normal prostate. Prostate. 2005 Sep 15; 65(1):52-7.
    View in: PubMed
    Score: 0.011
  16. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005 Mar 15; 103(6):1186-94.
    View in: PubMed
    Score: 0.011
  17. Protein expression profiling of endometriosis: validation of 2-mm tissue microarrays. Fertil Steril. 2004 Dec; 82(6):1681-3.
    View in: PubMed
    Score: 0.011
  18. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004 Oct 01; 10(19):6572-8.
    View in: PubMed
    Score: 0.011
  19. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004 Jul; 28(7):928-34.
    View in: PubMed
    Score: 0.011
  20. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004 Jun; 63(6):1191-7.
    View in: PubMed
    Score: 0.010
  21. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate. 2004 Feb 01; 58(2):193-9.
    View in: PubMed
    Score: 0.010
  22. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4792-801.
    View in: PubMed
    Score: 0.010
  23. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003 Oct 01; 63(19):6244-51.
    View in: PubMed
    Score: 0.010
  24. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003 Aug 01; 63(15):4662-70.
    View in: PubMed
    Score: 0.010
  25. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res. 2003 Jul-Aug; 23(4):3413-8.
    View in: PubMed
    Score: 0.010
  26. Neural cell adhesion molecule is upregulated in nerves with prostate cancer invasion. Hum Pathol. 2003 May; 34(5):457-61.
    View in: PubMed
    Score: 0.010
  27. Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. Urology. 2003 Apr; 61(4):870-5.
    View in: PubMed
    Score: 0.010
  28. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.010
  29. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002 Nov; 8(11):3419-26.
    View in: PubMed
    Score: 0.009
  30. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate. 2001 Nov 01; 49(3):213-23.
    View in: PubMed
    Score: 0.009
  31. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer. 2001 Sep 15; 92(6):1475-83.
    View in: PubMed
    Score: 0.009
  32. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.008
  33. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.008
  34. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 Oct 15; 60(20):5857-61.
    View in: PubMed
    Score: 0.008
  35. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999 Nov 15; 59(22):5719-23.
    View in: PubMed
    Score: 0.008
  36. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998 Aug; 4(8):1873-80.
    View in: PubMed
    Score: 0.007
  37. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer. 1996 Sep 15; 78(6):1267-71.
    View in: PubMed
    Score: 0.006
  38. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res. 1996 Apr; 2(4):635-40.
    View in: PubMed
    Score: 0.006
  39. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res. 1996 Feb; 2(2):399-401.
    View in: PubMed
    Score: 0.006
  40. Leu-7 immunoreactivity in cytologic specimens of thyroid lesions, with emphasis on follicular neoplasms. Diagn Cytopathol. 1995 Jun; 12(4):297-302.
    View in: PubMed
    Score: 0.006
  41. Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. J Urol. 1994 Jun; 151(6):1558-64.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.